MILDRONATE POTENTIAL FOR CORRECTING COGNITIVE DYSFUNCTION IN ELDERLY PATIENTS WITH ARTERIAL HYPERTENSION

Autor: Mikhail Statsenko, Nedogoda, S. V., Turkina, S. V., Tyshchenko, I. A., Poletaeva, L. V., Chumachok, E. V., Ledyaeva, A. A., Tsoma, V. V.
Jazyk: ruština
Rok vydání: 2011
Předmět:
Zdroj: Российский кардиологический журнал, Vol 0, Iss 4, Pp 91-95 (2011)
Scopus-Elsevier
ResearcherID
ISSN: 2618-7620
1560-4071
Popis: The study aimed to assess the effects of long-term and course mildronate therapy (500 mg/d) on cognitive function in elderly patients with arterial hypertension (AH) and cognitive dysfunction. This open, randomised, controlled comparative study in parallel groups (long-term therapy for 52 weeks, or two three-month courses over a year vs. standard therapy for 52 weeks) included 180 elderly patients with AH and cognitive dysfunction. Neuro-psychological examination included MMSE test, Reitan test, Wechsler test, test for speech activity, memory (10 words), and serial count, kinetic test, and MFI-20 test for asthenia assessment. Depression and anxiety symptoms were assessed with Beck and Tailor scales, respectively. Long-term mildronate therapy was the only treatment regimen improving all cognitive function parameters, compared to baseline and the control group. In the course mildronate therapy group, some cognitive function parameters did not change significantly, compared to baseline; however, the final values were not significantly different from those in the long-term mildronate therapy group. Course therapy was more effective than standard treatment in terms of improving the asthenia and anxiety scale parameters.
Databáze: OpenAIRE